FrancophonIA/ELRC3.0 huggingface dataset:
English: Irbesartan on its own has been approved in the European Union (EU) since 1997 under the names Karvea and Aprovel.
Estonian: Irbesartaan eraldi on olnud Euroopa Liidus ravimitena Karvea ja Aprovel heaks kiidetud alates 1997. aastast.
English: Care must be taken when using CoAprovel with other medicines that have an effect on blood potassium levels.
Estonian: Ettevaatlik tuleb olla CoAproveli kasutamisel koos teiste ravimitega, mis võivad mõjutada vere kaaliumisisaldust.
English: What is the risk associated with CoAprovel?
Estonian: Mis riskid CoAproveliga kaasnevad?
English: It is available as tablets (150 mg or 300 mg irbesartan and 12.5 mg hydrochlorothiazide; 300 mg irbesartan and 25 mg hydrochlorothiazide).
Estonian: Ravimit turustatakse tablettidena (150 mg või 300 mg irbesartaani ja 12,5 mg hüdroklorotiasiidi; 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi).
English: CoAprovel must also not be used in patients who have severe liver, kidney or bile problems, blood potassium levels that are too low or blood calcium levels that are too high.
Estonian: CoAprovelit ei tohi kasutada ka patsiendid, kellel on raske maksa-, neeru- või sapihaigus või vere kaaliumisisaldus on liiga väike või kaltsiumisisaldus liiga suur.
English: For the full list of all side effects reported with CoAprovel, see the package leaflet.
Estonian: CoAproveli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: CoAprovel is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.
Estonian: CoAprovel on ravim, mis sisaldab kaht toimeainet, irbesartaani ja hüdroklorotiasiidi.
English: Why has CoAprovel been approved?
Estonian: Miks CoAprovel heaks kiideti?
English: CoAprovel contains two active substances, irbesartan and hydrochlorothiazide.
Estonian: CoAprovel sisaldab kaht toimeainet, irbesartaani ja hüdroklorotiasiidi.
English: CoAprovel must not be used in people who are hypersensitive (allergic) to irbesartan, hydrochlorothiazide, sulfonamides, or any of the other ingredients.
Estonian: CoAprovelit ei tohi kasutada patsiendid, kes on irbesartaani, hüdroklorotiasiidi, sulfoonamiidide või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: CoAprovel is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone.
Estonian: CoAprovelit kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) täiskasvanutel, kellel ainult irbesartaani või hüdroklorotiasiidiga ei teki piisavat ravivastust.
English: It can be used with hydrochlorothiazide to treat hypertension.
Estonian: Seda tohib kasutada kõrgvererõhu raviks koos hüdroklorotiasiidiga.
English: Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended.
Estonian: Suuremaid annuseid kui 300 mg irbesartaani ja 25 mg hüdroklorotiasiidi üks kord ööpäevas ei soovitata.
English: How has CoAprovel been studied?
Estonian: Kuidas CoAprovelit uuriti?
English: What is CoAprovel?
Estonian: Mis on CoAprovel?
English: How is CoAprovel used?
Estonian: Kuidas CoAprovelit kasutatakse?
English: What benefit has CoAprovel shown during the studies?
Estonian: Milles seisneb uuringute põhjal CoAproveli kasulikkus?
English: CoAprovel was more effective than placebo (a dummy treatment) and than hydrochlorothiazide alone in reducing diastolic blood pressure.
Estonian: CoAprovel alandas diastoolset vererõhku paremini kui platseebo (näiv ravim) ja paremini kui ainult hüdroklorotiasiid.
English: CoAprovel may be added to some other treatments for hypertension.
Estonian: CoAprovelit tohib kasutada koos mõne muu kõrgvererõhuravimiga.
English: The medicine can only be obtained with a prescription.
Estonian: CoAprovel on retseptiravim.
English: The dose of CoAprovel to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before.
Estonian: CoAproveli annus sõltub patsiendi varasemast irbesartaani või hüdroklorotiasiidi annusest.
English: The studies of Karvea/Aprovel used with hydrochlorothiazide as separate tablets were used to support the use of CoAprovel.
Estonian: CoAproveli kasutamise toetuseks kasutati uuringuid, milles Karveat või Aproveli manustati koos hüdroklorotiasiidiga, kumbagi eraldi tablettidena.
English: What is CoAprovel used for?
Estonian: Milleks CoAprovelit kasutatakse?
English: CoAprovel in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi CoAprovelit kasutada koos aliskireeni sisaldavate ravimitega (essentsiaalse hüpertensiooni ravimid).
English: How does CoAprovel work?
Estonian: Kuidas CoAprovel toimib?
English: • If you are unsure whether you are affected, or if you have any questions, speak with your doctor or pharmacist.
Estonian: • Kui te ei ole kindel, kas siinne teave puudutab ka teid või kui teil on mingeid küsimusi, pöörduge oma arsti või apteekri poole.
English: Restrictions on use of medicines containing ergot derivatives
Estonian: Piirangud tungalteraderivaate sisaldavate ravimite kasutamisel
English: • The available efficacy data for the described indications were considered to be very limited.
Estonian: • Olemasolevad efektiivsusandmeid kirjeldatud näidustustel peeti piiratuiks.
English: Your doctor will confirm whether you should change to another treatment.
Estonian: Arst otsustab, kas te peate hakkama kasutama mõnda muud ravimit.
English: 25 October 2013 EMA/652753/2013
Estonian: 18. detsember 2013 EMA/27446/2014
English: On 27 June 2013, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended restricting the use of medicines containing ergot derivatives.
Estonian: 27. juunil 2013 soovitas Euroopa Ravimiameti inimravimite komitee piirata tungalteraderivaate sisaldavate ravimite kasutamist.
English: The review of ergot derivatives was initiated on 18 January 2012 at the request of France, under Article 31 of Directive 2001/83/EC.
Estonian: 18. jaanuaril 2012 algatati Prantsusmaa taotlusel tungalteraderivaate sisaldavate ravimite direktiivi 2001/83/EÜ artikli 31 kohane hindamine.
English: Patients were young (mean age 41 years-old), with a short time to onset after starting dihydroergotamine (less than 2 months, mean: 2 days).
Estonian: Sellised patsiendid olid enamasti noored (keskmine vanus 41 eluaastat) ja aeg sümptomite tekkeni pärast dihüdroergotamiini kasutamise alustamist oli lühike (alla 2 kuu; keskmine 2 päeva).
English: In addition, scientific advisory groups held in December 2012 and October 2013 did not consider there was evidence of a therapeutic need for ergot derivatives in the indications covered by the review.
Estonian: Peale selle ei leitud detsembris 2012 ja oktoobris 2013 toimunud teadusnõuanderühma koosolekutel, et läbivaatamisel käsitletud näidustustel on olemas tõendid tungalteraderivaatide terapeutilise vajaduse kohta.
English: The French medicines agency asked the CHMP to carry out an assessment of the benefit-risk balance and to issue an opinion on whether the marketing authorisations for these medicines should be maintained, varied, suspended or withdrawn across the European Union.
Estonian: Prantsusmaa ravimiamet palus inimravimite komiteel hinnata nende ravimite kasulikkuse ja riski tasakaalu ning esitada arvamus nende ravimite müügilubade säilitamise, muutmise, peatamise või tühistamise kohta kogu Euroopa Liidus.
English: In the EU, medicines containing ergot derivatives have been authorised by national procedures and have been marketed under various trade names.
Estonian: Euroopa Liidus on tungalteraderivaate sisaldavad ravimid saanud müügiloa riiklike menetluste kaudu ja neid on turustatud erinevate kaubanduslike nimetuste all.
English: − Orthostatic hypotension;
Estonian: − ortostaatiline hüpotensioon;
English: • Cases of ergotism or potentially related symptoms were most frequently reported with dihydroergotamine.
Estonian: • Ergotismi juhtudest ja sellega potentsiaalselt seotud sümptomitest on kõige sagedamini teatatud dihüdroergotamiini kasutamisel.
English: − Ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II);
Estonian: − vahelduva lonkamise täiendav ravi sümptomaatilise perifeersete arterite oklusiivse haiguse korral (PAOD II staadium);
English: At the request of a manufacturer of medicines containing dihydroergotoxine, one of the ergot derivatives, the CHMP carried out a re-examination of its opinion on this medicine.
Estonian: Dihüdroergotoksiini (mis on üks tungalteraderivaat) sisaldavate ravimite tootja palvel vaatas inimravimite komitee uuesti läbi oma otsuse selle ravimi kohta.
English: Fibrosis can be a serious, sometimes fatal disease, which is often difficult to diagnose because of delayed symptoms and may be irreversible.
Estonian: Fibroos võib olla raske ja mõnel juhul surmaga lõppev haigusseisund, mida on sümptomite hilise tekke tõttu sageli raske diagnoosida.
English: The re-examination concluded on 24 October 2013 with the Committee maintaining its previous recommendation, which will now be sent to the European Commission.
Estonian: Otsuse taasläbivaatamine lõppes 24. oktoobril 2013, kusjuures inimravimite komitee jäi oma varasemate soovituste juurde.
English: These indications were not included in the CHMP review; therefore these products will remain authorised and may continue to be used in those indications.
Estonian: Need näidustused ei olnud inimravimite komitee hindamise objektiks, seetõttu jäävad selliste ravimite müügiload alles ja neid võib antud näidustustel edasi kasutada.
English: The varying affinity for serotoninergic receptors of the different ergot derivatives, and the therapeutic doses used, may explain the differences observed in reporting frequencies for the fibrotic reactions.
Estonian: Eri tungalteraderivaatide erisugune afiinsus serotonergiliste retseptorite suhtes ja eri annused võivad selgitada erinevusi fibrootilistest reaktsioonidest teatamise sageduses.
English: Medicines containing ergot derivatives have an effect on blood circulation and they have been used for decades to treat conditions involving circulatory problems.
Estonian: Tungalteraderivaate sisaldavad ravimid avaldavad toimet vereringele ja neid on aastakümneid kasutatud haigusseisundite raviks, mille korral esinevad vereringehäired.
English: This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines.
Estonian: See otsus põhineb andmete hindamisel, mis näitavad nende ravimite kasutamisel suuremat fibroosi (liigne sidekoe teke, mis võib kahjustada elundeid ja organismi teisi kudesid) ja ergotismi (tungaltera mürgistuse sümptomid, nagu veresoonte spasmid ja verevoolu peetus) tekkimise riski.
English: The CHMP noted that there is a plausible mechanism by which ergot-derivatives could cause fibrosis and ergotism.
Estonian: Inimravimite komitee märkis, et on kindlaks tehtud tõenäoline mehhanism, mille kaudu võivad tungalteraderivaadid põhjustada fibroosi ja ergotismi.
English: benefits in these indications was very limited, the CHMP concluded that the benefits in the concerned indications did not outweigh the risk of fibrosis and ergotism.
Estonian: Võttes arvesse asjaolu, et tõendid nende ravimite kasulikkuse kohta nimetatud näidustustel olid väga piiratud, otsustas inimravimite komitee, et tungalteraderivaate sisaldavate ravimite kasulikkus eelmainitud näidustustel ei ole suurem kui fibroosi ja ergotismi tekkimise risk.
English: The CHMP noted the difficulty of diagnosing fibrosis (due to delayed onset of symptoms) and the probability of under-reporting of fibrotic reactions.
Estonian: Inimravimite komitee märkis, et fibroosi on keeruline diagnoosida (sümptomite hilise tekke tõttu), mistõttu on fibrootilised reaktsioonid tõenäoliselt alateatatud.
English: • Medicines containing substances known as ergot derivatives can have serious side effects, called fibrosis and ergotism.
Estonian: • Ravimid, mis sisaldavad toimeainena tungalteraderivaatide nimetuse all tuntud ühendeid, võivad põhjustada raskeid kõrvalnähtusid, mida nimetatakse fibroosiks ja ergotismiks.
English: − Ancillary treatment of Raynaud's syndrome;
Estonian: − Raynaud' sündroomi täiendav ravi;
English: Certain ergot derivatives have been used to treat conditions usually affecting elderly patients, such as peripheral arterial occlusive disease (PAOD, where the body's large arteries become obstructed) causing pain when walking, and Raynaud's syndrome (where the blood supply is blocked to the extremities, usually the fingers and toes), as well as eyesight disturbances due to blood circulation problems.
Estonian: Mõnesid tungalteraderivaate on kasutatud haigusseisundite raviks, mis esinevad enamasti eakatel patsientidel, nagu perifeersete arterite oklusiivne haigus (PAOD; haigus, mille korral keha suured arterid ummistuvad), mis põhjustab valu käimisel, ja Raynaud' sündroom (haigus, mille korral on häiritud verevool jäsemetesse, enamasti sõrmedesse ja varvastesse), aga ka vereringeprobleemidest tingitud nägemishäirete korral.
English: The review was initiated due to concerns identified by the French National Agency for the Safety of Medicine and Health Products (ANSM) in a national pharmacovigilance review in 2011.
Estonian: Üleeuroopalise hindamise algatas Prantsusmaa ravimiamet (ANSM) 2011. aastal läbi viidud riikliku ravimiohutuse järelevalve ülevaates kindlakstehtud asjaolude alusel.
English: − Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in the elderly (excluding Alzheimer's disease and other dementia);
Estonian: − kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatiline ravi eakatel patsientidel (v.a Alzheimeri tõbi ja muu dementsus);
English: In its review, the CHMP considered all available data on the benefits and risks of ergot derivatives, including data from clinical studies, post-marketing safety reports and the published literature.
Estonian: Eelmainitud hindamisel võttis inimravimite komitee arvesse kõiki olemasolevaid andmeid tungalteraderivaate sisaldavate ravimite kasulikkuse ja riskide kohta, sealhulgas kliiniliste uuringute, turustamisjärgsete ohutusaruannete ja kirjanduses avaldatud andmeid.
English: These medicines should no longer be used to treat several conditions involving blood circulation problems or problems with memory and sensation, or to prevent migraine headaches, since the risks are greater than the benefits in these indications.
Estonian: Nimetatud ravimeid ei tohi enam kasutada mitmete haigusseisundite raviks, näiteks vereringeprobleemid või mälu- ja tajumishäired ning migreenipeavalude ennetamine, sest mainitud ravimitega seotud riskid on nendel näidustustel suuremad kui nende kasulikkus.
English: The CHMP opinion follows a review of available safety and efficacy data on ergot derivatives in the above indications, including clinical studies, post-marketing data in Europe and the published literature:
Estonian: Inimravimite komitee arvamus võeti vastu pärast tungalteraderivaate sisaldavate ravimite ohutus- ja efektiivsusandmete ülevaatamist ülalmainitud näidustustel, sealhulgas kliiniliste uuringute, Euroopas turustamisjärgsed ja kirjanduses avaldatud andmed.
English: − Symptomatic treatment of veno-lymphatic insufficiency.
Estonian: − venolümfaatilise puudulikkuse sümptomaatiline ravi.
English: They have also been used for treating chronic pathological cognitive and neurosensorial impairment (problems with memory and sensation) and for preventing migraine headaches.
Estonian: Samuti on neid ravimeid kasutatud kroonilise patoloogilise kognitiivse ja neurosensoorse häire (mälu- ja tajumishäired) raviks ning migreenipeavalude ennetuseks.
English: Ergot derivatives are substances derived from a group of fungi commonly known as ergot.
Estonian: Tungalteraderivaadid on ained, mis on tuletatud tungalterana tuntud seente rühmast.
English: • Patients currently taking these medicines for any of the above indications should have their treatment reviewed at a routine (non-urgent) medical appointment.
Estonian: • Mõnel ülaltoodud näidustusel tungalteraderivaate sisaldavaid ravimeid kasutavate patsientide ravi tuleb tavalisel (mitte erakorralisel) plaanitud visiidil üle vaadata.
English: The severity of such adverse effects and their possible fatal outcome was underlined.
Estonian: Inimravimite komitee rõhutas selle kõrvalnähu raskust ja võimalikku lõppemist surmaga.
English: The pharmaceutical forms and the approved indications, strengths and doses vary in different EU countries.
Estonian: Erinevates Euroopa riikides on müügiluba erineva ravimvormi, näidustuste, tugevuse ja annustega ravimitel.
English: They will remain authorised for use by patients in those indications.
Estonian: Nendel näidustustel võivad patsiendid tungalteraderivaate sisaldavaid ravimeid edasi kasutada.
English: Several cases of ergotism or symptoms potentially related to ergotism (including severe cases of symptoms of constriction of peripheral blood vessels) were also identified with the other ergot derivatives.
Estonian: Ka teiste tungalteraderivaatide puhul on kindlaks tehtud mitmed ergotismi juhud või ergotismiga seotud võimalikud sümptomid (sealhulgas perifeersete veresoonte ahenemise sümptomite rasked juhud).
English: There were fewer reports of fibrotic reactions with the other ergot derivatives.
Estonian: Teiste tungalteraderivaatidega seoses on fibrootilistest reaktsioonidest teatatud harvemini.
English: Five ergot derivatives were considered in the CHMP review: dihydroergocristine, dihydroergotamine, dihydroergotoxine, nicergoline and the combination of dihydroergocryptine with caffeine.
Estonian: Inimravimite komitee hindas viit tungalteraderivaati: dihüdroergokristiin, dihüdroergotamiin, dihüdroergotoksiin, nikergoliin ning dihüdroergokrüptiini ja kofeiini kombinatsioon.
English: • Healthcare professionals should stop prescribing medicines containing dihydroergocristine, dihydroergotamine, dihydroergotoxine, nicergoline or a combination of dihydroergocryptine with caffeine, for any of the following indications:
Estonian: • Tervishoiuspetsialistid peavad lõpetama dihüdroergokristiini, dihüdroergotamiini, dihüdroergotoksiini, nikergoliini või dihüdroergokrüptiini ja kofeiini kombinatsiooni sisaldavate ravimite väljakirjutamise kõigil järgmistel näidustustel:
English: As a result, they should no longer be used in the EU to treat a number of conditions involving blood circulation problems (that usually affect elderly patients) or problems with memory and sensation, or to prevent migraine headaches, as the risks outweigh the benefits.
Estonian: Seetõttu ei tohi neid ravimeid Euroopa Liidus enam mitmete haigusseisundite raviks, sh vereringehäired (esinevad enamasti eakatel patsientidel), mälu- ja tajumishäired, või migreenipeavalude ennetamiseks kasutada, sest nende ravimitega seotud riskid on suuremad kui kasulikkus.
English: • Fibrosis was most frequently reported with dihydroergotamine, including retroperitoneal, cardiac, pulmonary and pleural fibrosis.
Estonian: • Fibroosist, sealhulgas retroperitoneaalsest, südame, kopsude ja pleura fibroosist, teatati kõige sagedamini dihüdroergotamiini kasutamisel.
English: − Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin;
Estonian: − eeldatavalt vaskulaarse põhjusega nägemisteravuse vähenemise ja nägemisvälja häirete täiendav ravi;
English: • Ergot derivatives are recognised as being capable of inducing fibrosis, in particular heart valve fibrosis, through serotoninergic receptor activation, which is extensively described in the literature.
Estonian: • Tungalteraderivaadid võivad serotonergiliste retseptorite aktiveerimise teel teadaolevalt põhjustada fibroosi, eelkõige südameklappide fibroosi.
English: − Acute retinopathies of vascular origin;
Estonian: − vaskulaarse põhjusega ägedate retinopaatiate ravi;
English: In some EU countries, certain ergot derivatives are also authorised for other indications not covered by the CHMP review, including other circulatory disorders, treatment of dementia (including Alzheimer's disease) and treatment of acute migraine.
Estonian: Mõnedes Euroopa Liidu liikmesriikides on teatud tungalteraderivaate sisaldavatel ravimitel müügiluba ka näidustustel, mis ei olnud inimravimite komitee hindamise objektiks, sealhulgas muud vereringehäired, dementsuse ravi (sealhulgas Alzheimeri tõbi) ja ägeda migreeni ravi.
English: In some EU Member States, ergot derivatives are also authorised for other indications such as treatment of dementia, including Alzheimer's disease, and treatment (as opposed to prevention) of acute migraine headache.
Estonian: Mõnedes Euroopa Liidu liikmesriikides on tungalteraderivaate sisaldavatel ravimitel müügiluba ka teistel näidustustel, nagu dementsuse (sealhulgas Alzheimeri tõve) ja ägedate migreenipeavalude (erinevalt migreenipeavalude ennetusest) ravi.
English: • Some ergot derivatives are approved in some EU Member States for use in other therapeutic indications, including other circulatory disorders, treatment of dementia (including Alzheimer's disease) and treatment of acute migraine.
Estonian: • Mõnedes Euroopa Liidu liikmesriikides on tungalteraderivaate sisaldavatel ravimitel müügiluba ka teistel näidustustel, nagu muud vereringehäired, dementsus (sealhulgas Alzheimeri tõbi) ja ägedad migreenipeavalud.
English: Ergot derivatives that are only indicated for these conditions will have their marketing authorisations suspended across the EU.
Estonian: Üksnes nende haigusseisundite raviks näidustatud tungalteraderivaate sisaldavate ravimite müügiload peatatakse kogu Euroopa Liidus.
English: The European Commission has already endorsed the CHMP opinion for 4 other ergot derivatives (dihydroergocristine, dihydroergotamine, nicergoline dihydroergocryptine), adopting a final legally binding decision on 27 September 2013.
Estonian: Euroopa Komisjon kinnitas inimravimite komitee arvamuse dihüdroergokristiini, dihüdroergotamiini, nikergoliini ja dihüdroergokrüptiini kohta 27. septembril 2013 ning inimravimite komitee arvamuse dihüdroergotoksiini kohta 18. detsembril 2013.
English: The CHMP opinion on dihydroergotoxine will now be forwarded to the European Commission, which will issue a final decision in due course.
Estonian: Inimravimite komitee soovitused edastati Euroopa Komisjonile, kes kiitis need heaks ja võttis vastu lõplikud õiguslikult siduvad otsused, mis kehtivad kogu Euroopa Liidus.
English: 7 vials + 7 pre-filled syringes + 14 injection needles + 14 alcohol swabs
Estonian: 7 viaali + 7 süstelit + 14 süstlanõelad + 14 alkoholitupsud
English: 1 vial + 1 pre-filled syringe + 2 injection needles + 2 alcohol swabs
Estonian: 1 viaal + 1 süstel + 2 süstlanõelad + 2 alkoholitupsud
English: Strength Pharmaceutical form Route of administration
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu (kontsentratsioon)
English: It is available as tablets (500 mg) and capsules (250 mg).
Estonian: Seda turustatakse tablettidena (500 mg) ja kapslitena (250 mg).
English: The full EPAR for Myclausen can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Myclauseni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Myclausen on 7 October 2010.
Estonian: Euroopa Komisjon andis Myclauseni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. oktoobril 2010.
English: In children aged between two and 18 years, the dose of Myclausen is calculated depending on height and weight.
Estonian: 2-18-aastastel lastel arvutatakse Myclauseni annus pikkuse ja kehakaalu järgi.